Medpace Holdings

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Medpace Holdings reports robust Q4 earnings amidst challenging biotech environment

Medpace Holdings delivered strong financial results in Q4 2022, showcasing revenue and EBITDA growth. The company addressed challenges such as cancellations and client funding risks while emphasizing strategic selectivity and revenue growth. Opportunities for growth through share-taking strategies and operational improvements were highlighted.

Medpace Holdings reports stellar Q1 results and projects strong 2023 guidance

Medpace Holdings demonstrated robust financial performance in Q1 2023, marked by significant revenue growth, improved profitability, and a strong backlog conversion outlook.
While facing funding challenges, the company's strategic initiatives, including share repurchases and updated guidance, highlight its resilience and growth potential.
By capitalizing on increased RFP flow, program progression, and strong backlog metrics, Medpace aims to sustain its growth trajectory and enhance market position.

Medpace Holdings reports robust Q2 earnings and growth opportunities

Medpace Holdings (MEDP) delivered a strong Q2 performance with significant revenue growth, solid financial metrics, and a healthy backlog, positioning the company for future success.
While facing challenges related to customer concentration and operational aspects, Medpace can capitalize on opportunities to drive revenue expansion, enhance market share, and improve operational efficiency.
Overall, Medpace's Q2 earnings call reflects a positive outlook with a focus on growth strategies, operational excellence, and addressing potential challenges to drive long-term value for stakeholders.

Medpace Holdings reports robust Q3 performance and optimistic 2024 outlook

Medpace Holdings delivered strong financial results in Q3 2023, with notable revenue growth and increased backlog, despite modest EBITDA growth.
The company's operational strengths include robust demand, good retention rates, and a stable employee base, supporting its growth trajectory.
While facing potential challenges in managing rapid growth, Medpace Holdings has opportunities for expansion through market diversification and service enhancements.

Medpace Holdings reports robust Q4 earnings and outlines growth targets

Medpace Holdings delivered impressive financial results in Q4 2023, showcasing strong revenue growth, increased net income, and a healthy EBITDA, supported by new business awards and share repurchases.
While the company faces challenges in sustaining high growth rates and addressing uncertainties in project funding, its stable financial position and strategic initiatives provide a foundation for future growth.
With a positive outlook for 2024 and opportunities for expansion and market share gains, Medpace is well-positioned to navigate industry challenges and drive continued success in the clinical research sector.

Medpace Holdings reports robust Q1 performance and optimistic 2024 outlook

Medpace Holdings delivered impressive Q1 results, showcasing strong revenue growth and profitability metrics.
The company's strategic focus on efficiency and growth opportunities bodes well for future performance and sustained success.
While challenges exist, Medpace's positive outlook, stable funding environment, and strategic initiatives position it for continued growth and value creation.

Medpace Holdings reports robust Q2 growth despite project cancellations

Medpace Holdings delivered strong financial performance in Q2 2024, with notable revenue and EBITDA growth. While facing challenges with project cancellations impacting backlog, the company remains optimistic about its future prospects, driven by a robust pipeline of opportunities and strategic hiring plans.

Medpace Holdings reports strong Q3 earnings, eyes growth opportunities

Medpace Holdings delivered strong financial results in Q3 2024, with revenue growth, increased profitability, and a healthy backlog, setting a positive trajectory for future performance.
While facing challenges such as backlog cancellations and lower RFP flow, the company's stable pricing, strategic focus, and operational efficiency position it well for growth.
Opportunities lie in improving order intake, capital deployment optimization, and maintaining shareholder value through disciplined decision-making and market expansion.
Overall, Medpace Holdings' performance reflects resilience, strategic clarity, and potential for growth, underpinned by operational efficiency and financial stability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HealthEquity

Investors interested in stocks from the Medical Services sector have probably already heard of HealthEquity (HQY) and Medpace (MEDP). But which of these two companies is the best option for those looking for undervalued stocks?

HQY vs. MEDP: Which Stock Is the Better Value Option?

LOS ANGELES, CA / ACCESSWIRE / September 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Looking Into Whether Medpace Holdings, Inc. Violated Securities Laws And Affected Investors Are Urged To Reach Out

In the latest trading session, Medpace (MEDP) closed at $339.38, marking a +1.08% move from the previous day.

Medpace (MEDP) Ascends But Remains Behind Market: Some Facts to Note

LOS ANGELES, CA / ACCESSWIRE / September 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

An Inquiry Has Been Launched Into Medpace Holdings Inc. For Potential Securities Fraud And The Schall Law Firm Seeks Public Participation

LOS ANGELES, CA / ACCESSWIRE / September 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Looking Into Whether Medpace Holdings Inc Violated Securities Regulations And Investors Are Urged To Reach Out

LOS ANGELES, CA / ACCESSWIRE / September 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Medpace Holdings, Inc. May Have Committed Securities Fraud And Stockholders Are Encouraged To Assist The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites Investors To Reach Out About An Investigation Into Medpace Holdings Inc's Possible Securities Fraud

LOS ANGELES, CA / ACCESSWIRE / September 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Medpace Holdings Inc. May Have Committed Securities Law Violations And Shareholders Are Urged By The Schall Law Firm To Join An Inquiry

LOS ANGELES, CA / ACCESSWIRE / September 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Looking Into Medpace Holdings Inc For Potential Securities Fraud And Investors Are Invited To Contribute

LOS ANGELES, CA / ACCESSWIRE / September 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Medpace Holdings Inc. May Have Violated Securities Regulations And The Schall Law Firm Seeks Participation From Shareholders

LOS ANGELES, CA / ACCESSWIRE / September 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Are Invited To Help The Schall Law Firm Look Into Whether Medpace Holdings Inc Committed Securities Fraud

LOS ANGELES, CA / ACCESSWIRE / August 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Medpace Holdings Inc. May Have Violated Securities Regulations And The Schall Law Firm Wants The Public To Assist In An Inquiry

LOS ANGELES, CA / ACCESSWIRE / August 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Are Invited By The Schall Law Firm To Take Part In An Investigation Into Medpace Holdings Inc For Possible Fraud

LOS ANGELES, CA / ACCESSWIRE / August 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Inquiring Into Whether Medpace Holdings Inc. Committed Securities Fraud And Shareholders Are Urged To Reach Out

NEW YORK, NY / ACCESSWIRE / August 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medpace Holdings, Inc. ("Medpace") (NASDAQ:MEDP) concerning possible violations of federal securities laws. On July 22, 2024, after market hours, MedPace announced mixed financial results for the second quarter of 2024 and then slashed its revenue guidance for the third quarter and remainder of the year.

MEDP ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Medpace Holdings, Inc.

LOS ANGELES, CA / ACCESSWIRE / August 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Medpace Holdings Inc Is Being Investigated For Securities Law Infractions And The Schall Law Firm Encourages Investors To Participate

NEW YORK, NY / ACCESSWIRE / August 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medpace Holdings, Inc. ("Medpace") (NASDAQ:MEDP) concerning possible violations of federal securities laws. On July 22, 2024, after market hours, MedPace announced mixed financial results for the second quarter of 2024 and then slashed its revenue guidance for the third quarter and remainder of the year.

Medpace Holdings, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - MEDP

LOS ANGELES, CA / ACCESSWIRE / August 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Shareholders Can Reach Out To The Schall Law Firm About An Inquiry Into Medpace Holdings Inc For Possible Securities Fraud

NEW YORK, NY / ACCESSWIRE / August 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medpace Holdings, Inc. ("Medpace") (NASDAQ:MEDP) concerning possible violations of federal securities laws. On July 22, 2024, after market hours, MedPace announced mixed financial results for the second quarter of 2024 and then slashed its revenue guidance for the third quarter and remainder of the year.

Medpace Holdings, Inc. (MEDP) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates

LOS ANGELES, CA / ACCESSWIRE / August 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Looking Into Whether Medpace Holdings Inc Violated Securities Laws And Investors Are Invited To Take Part

LOS ANGELES, CA / ACCESSWIRE / August 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

An Investigation For Securities Fraud Has Been Launched Into Medpace Holdings Inc And The Schall Law Firm Is Seeking Stockholders To Participate

NEW YORK, NY / ACCESSWIRE / August 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medpace Holdings, Inc. ("Medpace") (NASDAQ:MEDP) concerning possible violations of federal securities laws. On July 22, 2024, after market hours, MedPace announced mixed financial results for the second quarter of 2024 and then slashed its revenue guidance for the third quarter and remainder of the year.

Medpace Being Investigated on Behalf of Medpace Holdings, Inc. Investors. Contact Levi & Korsinsky For Details.

LOS ANGELES, CA / ACCESSWIRE / August 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Starting An Inquiry Into Medpace Holdings Inc For Violations Of Securities Regulations And Investors Are Invited To Join

LOS ANGELES, CA / ACCESSWIRE / August 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Medpace Holdings Inc Is Being Looked Into By The Schall Law Firm For Possible Securities Fraud And Impacted Stockholders Are Urged To Participate

LOS ANGELES, CA / ACCESSWIRE / August 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

News for Medpace Holdings Stock (MEDP)